Founded Year

2015

Stage

Series B | Alive

Total Raised

$31.3M

About Holmusk

Holmusk is a data science and digital therapeutics company with a global presence that is dedicated to establishing objective evidence as a core utility to the treatment of mental health and chronic diseases. Holmusk's proprietary technology powers data-driven medicine that leverages analytic and digital tools to address the unmet need in healthcare and pharma-life science.

Holmusk Headquarter Location

71 Ayer Rajah Crescent #06-07/08/09

139951,

Singapore

+65-6250-4233

ESPs containing Holmusk

The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.

EXECUTION STRENGTHMARKET STRENGTHLEADERHIGHFLIEROUTPERFORMERCHALLENGER
Healthcare / Biopharmaceuticals

Companies in this market offer alternative datasets that can supplement clinical trial data and improve the likelihood of trial success. These companies collect data from a variety of sources, such as patient registries, EHRs, insurance databases, social media, and patient research networks.

Holmusk named as Highflier among 15 other companies, including Datavant, Syapse, and Evidation.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Holmusk's Products & Differentiation

See Holmusk's products and how their products differentiate from alternatives and competitors

  • NeuroBlu

    NeuroBlu democratizes access to one of the largest and deepest research-grade, real-world datasets in behavioral health enabling new dimensions of exploration and insight generation for the life sciences industry, academia, and regulators alike.

  • Subscribe to see more

    We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.

  • Subscribe to see more

    We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.

  • Subscribe to see more

    We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.

  • Subscribe to see more

    We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.

Research containing Holmusk

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Holmusk in 2 CB Insights research briefs, most recently on Jun 2, 2022.

Expert Collections containing Holmusk

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Holmusk is included in 8 Expert Collections, including Digital Health.

D

Digital Health

13,489 items

Companies developing and enabling evidence-based, software-driven therapeutic interventions to prevent, manage, or treat a medical disorder or disease. (*Scope follows the Digital Therapeutics Alliance definition)

M

Mental Health Tech

1,215 items

This collection includes companies applying technology to problems of emotional, psychological, and social well-being. Examples include companies working in areas such as substance abuse, eating disorders, stress reduction, depression, PTSD, and anxiety.

C

Clinical Trials Tech

326 items

Companies developing products and services to streamline drug R&D, from drug discovery, pre-clinical testing, and clinical trials.

A

Artificial Intelligence

9,051 items

This collection includes startups selling AI SaaS, using AI algorithms to develop their core products, and those developing hardware to support AI workloads.

B

Biopharma Tech

5,567 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

D

Diabetes

1,750 items

Latest Holmusk News

Prevalence of anxiety, depression in U.S. adults elevated in first year of pandemic

Jun 22, 2022

Disclosures: Kessler reports receiving personal fees from Datastat Inc., Holmusk, RallyPoint Networks Inc., and Sage Therapeutics, and reported holding stock options in Mirah, PYM and Roga Sciences during the conduct of the study. Please see the study for all other authors’ relevant financial disclosures. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Please try again later. If you continue to have this issue please contact customerservice@slackinc.com . Back to Healio Prevalence of clinically significant anxiety and depression among adults in the United States increased during the first year of the COVID-19 pandemic compared with prior years, according to a study published in JAMA Network Open. “Concerns about adverse mental health effects of COVID-19 have been raised since the beginning of the pandemic,” Ronald C. Kessler, PhD, of the department of health care policy at Harvard Medical School, and colleagues wrote. “Many empirical papers subsequently investigated the association of the pandemic with mental health, and most concluded that the pandemic cause dramatic increases in anxiety and depression.” Source: Adobe Stock. Kessler and colleagues examined survey data for clinically significant diagnoses of anxiety and depression among adults during the first year of the pandemic. The study obtained information from the CDC’s Behavioral Risk Factor Surveillance System (BRFSS), a state-based monthly telephone survey in which 1,429,354 adults responded (1,093,663 from 2017 to 2019; 335,691 from March to December 2020). The primary outcome was estimated 30-day prevalence of anxiety and depression based on a single BRFSS item calibrated to a score of six or higher on the four-item Patient Health Questionnaire. Results showed that median within-state response rates were 45.9% to 49.4% in during the 2017 to 2019 survey period, and 47.9% in 2020. Estimated 30-day prevalence of clinically significant anxiety and depression was 0.4 (95% CI, 0 to 0.7) percentage points higher in March to December 2020 (12.4%) than March to December 2017 to 2019 (12.1%). This estimated increase was limited, however, to students (2.4 [95% CI, 0.8 to 3.9] percentage points) and the employed (0.9 [95% CI, 0.5 to 1.4] percentage points). “Although it is impossible to predict future trends with accuracy there are some promising signs in the expansion of tele-mental health care and increased use of scalable interventions to address increasing demand for treatment of emotional problems,” Kessler and colleagues wrote. Read more about

Holmusk Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Holmusk Rank

  • When was Holmusk founded?

    Holmusk was founded in 2015.

  • What is Holmusk's latest funding round?

    Holmusk's latest funding round is Series B.

  • How much did Holmusk raise?

    Holmusk raised a total of $31.3M.

  • Who are the investors of Holmusk?

    Investors of Holmusk include Heritas Capital, Optum Ventures, Health Catalyst Capital Management, dRx Capital, Northwell Holdings & Ventures and 5 more.

  • Who are Holmusk's competitors?

    Competitors of Holmusk include Owkin and 8 more.

  • What products does Holmusk offer?

    Holmusk's products include NeuroBlu and 4 more.

  • Who are Holmusk's customers?

    Customers of Holmusk include AIA, Otsuka and Mersey Care NHS Foundation Trust.

You May Also Like

Evidation Logo
Evidation

Evidation measures health in everyday life and enables anyone to participate in research and health programs. Evidation is a two-sided platform that connects individuals and enterprises. On the consumer side, the company assists individuals to participate in research including testing of digital health programs. On the enterprise side, Evidation provides biopharma, med-tech, big tech, academic institutions, professional societies, and government partners the ability to: generate evidence; and design, test, and deploy programs that motivate evidence-based action.

nference Logo
nference

nference offers a platform that enables a diverse set of applications ranging from R&D to commercial strategy and operations in the life sciences ecosystem. nference makes biomedical knowledge computable and builds its AI platform to serve as the connective fabric for various silos of information that exist across health care enterprises.

Owkin Logo
Owkin

Owkin specializes in AI technologies applied to clinical research with the aim of developing better drugs and treatments for patients. The company's purpose is to empower researchers in hospitals, universities and the biopharma industry to i) understand why drug efficacy varies from patient to patient, ii) improve the drug development process and iii) to help identify key drugs and treatments for each individual patient to improve patient outcomes. The company's precision medicine platform aims to enable medical insights for drug discovery and development by connecting life sciences firms with academic researchers and hospitals. The Owkin platform aims to enable partners to uncover siloed datasets while maintaining patient privacy and securing proprietary data using Federated Learning and innovative collaborative AI technology.

Syapse Logo
Syapse

Syapse develops applications that enable the use of omics profiles in diagnosing and treating patients at diagnostic companies, research institutions, medical centers, and payers. The Syapse Discovery application provides an end-to-end solution for companies and laboratories deploying next-generation sequencing-based diagnostics, from patient sample received to physician report delivered. Discovery's configurable semantic data structure enables users to bring omics data together with traditional medical information to develop and deliver diagnostic tests. The platform's open interfaces enable bioinformaticians and biologists to use their favorite computational tools and annotations.

Imagia Canexia Health Logo
Imagia Canexia Health

Imagia Canexia Health enables collaborative AI by providing outcome-based structured clinical data and federated learning capabilities across multiple sources and researchers. Imagia's Evidens Platform uses routine clinical patient data, designed to deliver care, into outcome-based structured information appropriate for AI biomarker discovery. Imagia Healthcare delivers AI clinical solutions to B2B partners, as R&D tools, digital health products, or fully regulated software-as-medical-devices validated through the ISO13485 MDSAP certified quality system.

Unlearn Logo
Unlearn

Unlearn creates a machine learning (ML) platform for creating Intelligent Control Arms with Digital Twins. Unlearn is working closely with biopharma companies and regulators to ensure its methods meet scientific and regulatory standards.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.